<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04109404</url>
  </required_header>
  <id_info>
    <org_study_id>29BRC19.0030</org_study_id>
    <nct_id>NCT04109404</nct_id>
  </id_info>
  <brief_title>Meningiomas and Treatment With CYPROTERONE ACETATE or Progestin</brief_title>
  <acronym>MAP</acronym>
  <official_title>Meningiomas and Treatment With CYPROTERONE ACETATE or Progestin: Retrospective Study in Patients Followed at the CHRU of Brest</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Brest</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Brest</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Investigators observe an increase risk of meningioma in patient treated by CYPROTERONE&#xD;
      ACETATE or other form of progestin. Investigatorsdiscribe caractéristics of meningioma and&#xD;
      treatement of the patients follow up in CHRU of Brest&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Retrospective study in CHRU of brest, the investigators selected patient with history of&#xD;
      méningioma and treated by CYPROTERONE ACETATE, CHLORMADINONE ACETATE and NOMEGESTROL ACETATE&#xD;
      essentially The investigators excluded patient with risk factor of meningioma added at&#xD;
      hormonal treatment exposition The investigators discribe the caractéristique of patients:&#xD;
      age, sex, duration of the treatment, the caractéristique of the meningioma: localization,&#xD;
      grade, hormonal receptors, treatment by surgery or radiotherapy and changing after&#xD;
      discontinuation of treatment&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 25, 2019</start_date>
  <completion_date type="Actual">June 1, 2019</completion_date>
  <primary_completion_date type="Actual">June 1, 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Diagnosis of meningiomas caracteristics</measure>
    <time_frame>12 months</time_frame>
    <description>meningiomas caracteristics in patient treated with CYPROTERONE ACETATE or Progestin description</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>prescription status of progestogenic treatment</measure>
    <time_frame>12 months</time_frame>
    <description>indications, duration of treatment, name and type of treatment</description>
  </secondary_outcome>
  <enrollment type="Actual">110</enrollment>
  <condition>Meningioma</condition>
  <eligibility>
    <study_pop>
      <textblock>
        6 men/110, 104 women/110 sex ratio 17.5:1 average duration of follow up: 5.5 years average&#xD;
        age at diagnosis: 54 +/- 13 years&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  minimum 18 years&#xD;
&#xD;
          -  medical follow up in CHRU of Brest&#xD;
&#xD;
          -  treated by CYPROTERONE ACETATE and/or CHLORMADINONE ACETATE NOMEGESTROL ACETATE,&#xD;
             PROGESTERONE , DYDROGESTERONE PROMEGESTONE , NORETHISTERONE, LEVONORGESTREL ,&#xD;
             oestroprogestogenic contraception&#xD;
&#xD;
          -  meningioma after treatement by progestin or CYPROTERONE ACETATE&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  history ofbreast cancer&#xD;
&#xD;
          -  history of cerebral radiotherapy&#xD;
&#xD;
          -  history of neurofibromatosis&#xD;
&#xD;
          -  meningioma before treatement by progestin or CYPROTERONE ACETATE&#xD;
&#xD;
          -  minor patient&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Véronique KERLAN, PH</last_name>
    <role>Principal Investigator</role>
    <affiliation>Service d'Endocrinologie-Diabétologie - CHRU de Brest</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Département de Nutrition - CHRU de Brest</name>
      <address>
        <city>Brest</city>
        <zip>29200</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <reference>
    <citation>Bernat AL, Oyama K, Hamdi S, Mandonnet E, Vexiau D, Pocard M, George B, Froelich S. Growth stabilization and regression of meningiomas after discontinuation of cyproterone acetate: a case series of 12 patients. Acta Neurochir (Wien). 2015 Oct;157(10):1741-6. doi: 10.1007/s00701-015-2532-3. Epub 2015 Aug 12.</citation>
    <PMID>26264069</PMID>
  </reference>
  <reference>
    <citation>S. Froelich, &quot;Does cyproterone acetate promote multiple meningiomas?,&quot; 2009.</citation>
  </reference>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>September 23, 2019</study_first_submitted>
  <study_first_submitted_qc>September 27, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">September 30, 2019</study_first_posted>
  <last_update_submitted>October 10, 2019</last_update_submitted>
  <last_update_submitted_qc>October 10, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 11, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>meningioma,</keyword>
  <keyword>progestin,</keyword>
  <keyword>cyproterone acetate</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Meningioma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

